Royalty Pharma Plc stock is traded at $69.31, with a volume of 2,951,217. It is up +0.49% in the last 24 hours and up +22.52% over the past month. Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Previous Close:
$68.97
Open:
$68.77
24h Volume:
2,951,217
Relative Volume:
0.80
Market Cap:
$30.86B
Revenue:
$2.44B
Net Income/Loss:
$1.36B
P/E Ratio:
36.30
EPS:
$1.91
Net Cash Flow:
$574.14M
1W Performance:
+2.99%
1M Performance:
+22.52%
6M Performance:
+30.16%
1Y Performance:
+74.45%
1-Day Range:
$68.14$69.43
1-Week Range:
$66.93$70.37
52-Week Range:
$37.31$70.37
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma PlcSector
HealthcareIndustry
BiotechnologyPhone
(212) 883-0200Address
110 EAST 59TH STREET, NEW YORK, NY, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS